This post contains spoilers for the series finale of Stranger Things. The Stranger Things kids are all right. They’re a little banged up and eternally trauma bonded, haunted by violent images of the ...

Stranger Things 5: The Finale took us down many winding roads. And, it kind of felt like it had five separate endings, given all the different pieces of its epilogue ...

Not content to just put out one twisty movie at the holiday season with Wake Up Dead Man, Netflix decided to open the floodgates – pun fully intended – with South Korean disaster movie The Great Flood ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Are you a multitasker, a free spirit, or an overly optimistic planner? Experts say these are some of the traits that explain why some people are always running behind. Some people just seem wired to ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Guillermo Del Toro’s Frankenstein is now out on Netflix, with the monster (played by Jacob Elordi) shown to be far more human than his titular creator. The ending of the Netflix film differs from both ...

Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...